- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05051722
Gebruikmaken van Methylated DNA Markers (MDM's) bij de detectie van endometriumkanker, eierstokkanker en baarmoederhalskanker (ECHO)
Gebruik maken van gemethyleerde DNA-markers (MDM's) bij de detectie van endometriumkanker, eierstokkanker en baarmoederhalskanker: een klinische fase II-studie
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.
This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Detection of endometrial, ovarian, and cervical cancers at an early stage vastly increases the chances of cure and may also avert morbidity secondary to surgical staging, radiation, and/or chemotherapy. Despite the great successes of cervical cancer screening, comparable early detection methods for other gynecologic cancers and their precursors are not available. While nearly 1.5 million women per year in the United States are evaluated for abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB), the most common symptom of endometrial cancer, most undergo an invasive diagnostic biopsy with the finding of benign etiology.
Vaginal bleeding is often the only presenting symptom of women ultimately diagnosed with endometrial cancer (EC) or its precursor lesion, endometrial hyperplasia(EH). More than 90% of women with EC present with vaginal bleeding. Cervical cancer and cervical dysplasia can present as intermenstrual bleeding, post-coital bleeding, or other abnormal vaginal bleeding. However, most women who present with AUB or PMB have a benign etiology.
There are approximately 70 million women ≥45 years of age in the United States based on the most recent census data. Between 4-11% of women will be worked up for perimenopausal AUB or PMB in their lifetime. As only 5-10% of those women will have an EC or EH, there is a great clinical need for a less invasive clinical diagnostic test that can reliably distinguish between benign uterine bleeding and bleeding associated with an underlying endometrial cancer, cervical cancer, or a precursor lesion.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Maureen A Lemens, BSN
- Telefoonnummer: 507-293-1487
- E-mail: lemens.maureen@mayo.edu
Studie Contact Back-up
- Naam: Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Werving
- Mayo Clinic
-
Hoofdonderzoeker:
- Kristina A. Butler, M.D.
-
Contact:
- Favy Trujillo
- Telefoonnummer: 480-574-1468
- E-mail: trujillo.faviola@mayo.edy
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Mayo Clinic
-
Contact:
- Ashley N Shelton, CRC
- Telefoonnummer: 504-953-1594
- E-mail: Shelton.Ashley@mayo.edu
-
Hoofdonderzoeker:
- Tri A. Dinh, M.D.
-
Miami, Florida, Verenigde Staten, 33173
- Werving
- Genoma Research, Inc.
-
Contact:
- Laura Lucia, BHSc, CRC
- Telefoonnummer: 305-392-1264
- E-mail: lauralucia@genoma.comcastbiz.net
-
Hoofdonderzoeker:
- Guillermo Lievano, D.O.
-
Onderonderzoeker:
- Itsel Cardenas, PhD, APRN
-
Miami, Florida, Verenigde Staten, 33156
- Actief, niet wervend
- My GYN Care
-
Orlando, Florida, Verenigde Staten, 32806
- Werving
- Orlando Health
-
Contact:
- Donya Shahnavaz, CRC
- Telefoonnummer: 321-841-7303
- E-mail: donya.shahnavaz@orlandohealth.com
-
Contact:
- Bianca Henry, CRC
- E-mail: bianca.henry@orlandohealth.com
-
Hoofdonderzoeker:
- Shelly M. Seward, M.D.
-
Pembroke Pines, Florida, Verenigde Staten, 33029
- Actief, niet wervend
- Signature Women's Healthcare, LLC
-
Sarasota, Florida, Verenigde Staten, 34239
- Werving
- Sarasota Memorial Health Care System
-
Hoofdonderzoeker:
- Toni P Kilts, D.O.
-
Contact:
- Anna Turnbull
- E-mail: Anna-Turnbull@smh.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30318
- Werving
- Piedmont Healthcare
-
Contact:
- Dionne Jean, CRC
- Telefoonnummer: 404-425-7927
- E-mail: dionne.jean@piedmont.org
-
Hoofdonderzoeker:
- Leda Portia A. Gattoc, M.D.
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Contact:
- Veronika Sesari
- E-mail: vseseri@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Kathryn Mills, M.D.
-
Contact:
- Calla O'Connor, MPH
- E-mail: calla.oconnor@bsd.uchicago.edu
-
Evergreen Park, Illinois, Verenigde Staten, 60805
- Actief, niet wervend
- Providea Health Partners, LLC
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Werving
- Ochsner Clinic Foundation
-
Hoofdonderzoeker:
- Diogo Torres, M.D.
-
Contact:
- Ashley Samuel, CRC
- Telefoonnummer: 504-703-2658
- E-mail: ashley.samuel@ochsner.org
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Henry Ford Health
-
Contact:
- Omayma Al Jabiry, CRC
- E-mail: oaljab1@hfhs.org
-
Contact:
- Ishita Narula, CRC
- E-mail: inarula1@hfhs.org
-
Hoofdonderzoeker:
- Ilinca Lupea, M.D.
-
Saginaw, Michigan, Verenigde Staten, 48602
- Werving
- Valley OB-GYN Clinic
-
Contact:
- Jacqueline Lang, CCRC
- Telefoonnummer: 989-272-9065
- E-mail: jacqueline.lang@elligodirect.com
-
Hoofdonderzoeker:
- Olivia A. Phifer-Combs, M.D.
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic
-
Contact:
- Maureen A Lemens, BSN
- Telefoonnummer: 507-293-1487
- E-mail: lemens.maureen@mayo.edu
-
Hoofdonderzoeker:
- Jamie N. Bakkum-Gamez, MD
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39213
- Werving
- University of Mississippi Medical Center
-
Hoofdonderzoeker:
- Rodney Rocconi, M.D.
-
Contact:
- Kenna H Nettles, PA-C
- Telefoonnummer: 601-815-5963
- E-mail: knettles1@umc.edu
-
Contact:
- Adriana Dodson, RN
- Telefoonnummer: 601-984-1962
- E-mail: adodson2@umc.edu
-
-
New York
-
Howard Beach, New York, Verenigde Staten, 11414
- Werving
- The Woman's Health Pavilion
-
Contact:
- Monica Martinez, CRC
- Telefoonnummer: 718-843-6300
- E-mail: mmartinez@ilovemygyn.com
-
Hoofdonderzoeker:
- Andre H. Saad, M.D.
-
Westbury, New York, Verenigde Staten, 11590
- Werving
- The Woman's Health Pavilion
-
Contact:
- Monica Martinez, CRC
- Telefoonnummer: 718-843-6300
- E-mail: mmartinez@ilovemygyn.com
-
Hoofdonderzoeker:
- Andre H. Saad, M.D.
-
-
North Dakota
-
Grand Forks, North Dakota, Verenigde Staten, 58206
- Werving
- Altru Health System
-
Hoofdonderzoeker:
- Collette Lessard, M.D.
-
Contact:
- Morgan Podell, CRC
- Telefoonnummer: 701-780-6161
- E-mail: mlpodell@altru.org
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Cleveland Clinic Foundation
-
Contact:
- Tori Carpenter, CRC
- E-mail: carpent3@ccf.org
-
Contact:
- Sarah Neale, CRC
- E-mail: neales@ccf.org
-
Hoofdonderzoeker:
- Michelle L. Kuznicki, M.D.
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77018
- Werving
- Total Women's Care of the Heights
-
Hoofdonderzoeker:
- Vonne Jones, M.D.
-
Contact:
- Tatiana Rivera
- Telefoonnummer: 346-330-5302
- E-mail: tatiana.rivera@twcheights.com
-
Katy, Texas, Verenigde Staten, 77450
- Werving
- Medical Colleagues of Texas, LLP
-
Contact:
- Erika Keller, CRC
- Telefoonnummer: 281-769-8674
- E-mail: erika.keller@elligodirect.com
-
Hoofdonderzoeker:
- Kelly A. McCullagh, M.D.
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23219
- Werving
- Virginia Commonwealth University/ Massey Cancer Center
-
Hoofdonderzoeker:
- Chelsea Salyer, M.D.
-
Contact:
- Priyanka Doneparthi, CRC
- E-mail: doneparthip@vcu.edu
-
Contact:
- Morgan DeHart, CRC
- Telefoonnummer: 804-827-1266
- E-mail: dehart2@vcu.edu
-
-
Wisconsin
-
Eau Claire, Wisconsin, Verenigde Staten, 54703
- Werving
- Mayo Clinic Health System - Northwest Wisconsin
-
Contact:
- Stephanie L Larson, ACRC
- Telefoonnummer: 715-838-1976
- E-mail: larson.stephanie3@mayo.edu
-
Contact:
- Christina M Scinto, ACRC
- Telefoonnummer: 715-464-8172
- E-mail: cinto.christina@mayo.edu
-
Hoofdonderzoeker:
- Blenda Yun, M.D.
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Werving
- Mayo Clinic Health System - Southwest Wisconsin
-
Contact:
- Kate L Zboralski, ACRC
- Telefoonnummer: 608-392-9521
- E-mail: zboralski.kathryn@mayo.edu
-
Contact:
- Taylor Cammer, ACRC
- Telefoonnummer: 608-392-9280
- E-mail: cammer.taylor@mayo.edu
-
Hoofdonderzoeker:
- Rebecca A. Scarseth, D.O.
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Actief, niet wervend
- Medical College of Wisconsin
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients presenting to a GYN or GYN Surgery Clinic for evaluation of symptoms or for consultation and planned procedures as outlined in the seven study cohort descriptions.
Beschrijving
Inclusion Criteria for Cohort 1:
Patients will be ≥45 years of age and meet one of the following criteria:
- Abnormal uterine bleeding
- Postmenopausal bleeding
OR
Patients ages 18 - 44 years of age and meet these criteria
- Abnormal uterine bleeding
- One risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use)
Exclusion Criteria for Cohort 1:
- Prior hysterectomy
- Current known pregnancy diagnosis
- Any prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia
- Current biopsy-proven endometrial cancer or endometrial hyperplasia
- Current biopsy-proven benign endometrial polyp
- Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium
Inclusion Criteria for Cohort 2:
Patients will be ≥18 years of age and meet at least one of the following criteria:
- Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection
- Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc)
Exclusion Criteria for Cohort 2:
- Undergoing surgical procedure for recurrent or metastatic EC
- Received preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven cervical cancer
- Presence of concomitant biopsy-proven cervical dysplasia
- Any prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Prior intervention or surgery with intent to completely remove the target pathology
Inclusion Criteria for Cohort 3:
Patients will be ≥18 years of age, have a cervix and meet at least one of the following criteria:
- History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy
- Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated
- Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)
Exclusion Criteria for Cohort 3:
- History of pelvic or vaginal radiotherapy
- Prior total hysterectomy (cervix removed) for any indication
- Current known pregnancy diagnosis
- Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass
- Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode
Inclusion Criteria for Cohort 4:
Patients will be ≥45 years of age and should meet at least one of the following criteria:
- Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps.
- Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.
Exclusion Criteria for Cohort 4:
- Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis
- Any surgery within the past 3 months
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven gynecologic cancer
- Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
- Prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis
- Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode
Inclusion Criteria for Cohort 5:
Patients with a uterus will be ≥45 years of age and should meet the following criteria:
- Presenting for GYN wellness exam, ± Pap test
- No change in medical conditions, new diagnoses, or new medications within the past 6 months
Exclusion Criteria for Cohort 5:
- Pap test or cervical biopsy within the past 1 month
- Endometrial biopsy or office hysteroscopy within the past 1 month
- Any surgery within the past 3 months
- Prior hysterectomy
- Current known pregnancy diagnosis
- Prior or current biopsy-proven gynecologic cancer
- Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
- Prior pelvic or vaginal radiotherapy
- Any prior cancer (except basal cell skin cancer) within the past 5 years
- Chemotherapy within the past 5 years
- Criteria met for inclusion in any of the other study cohorts
Inclusion Criteria for Cohort 6:
Patients ≥50 years of age and:
- Postmenopausal
- At least 1 intact ovary
- Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer)
- Planned surgery for the adnexal mass
- For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)
Exclusion criteria for Cohort 6:
- Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn)
- Chemotherapy for cancer treatment within the past 5 years prior to collection
- Clinically suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection
- Surgical candidates for recurrent ovarian cancer
- History of pelvic or vaginal radiation therapy
- Known current synchronous endometrial cancer or hyperplasia
- Known current cervical, vaginal, or vulvar dysplasia
Inclusion criteria for Cohort 7:
Women will be ≥18 years of age and meet the following criteria:
- Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology
- Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy
- At least one intact ovary
- For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)
Exclusion criteria for Cohort 7:
- Patients with recurrent OC
- Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years
- Chemotherapy for cancer treatment within the past 5 years prior to collection
- History of pelvic or vaginal radiation therapy
- Known current synchronous endometrial cancer or hyperplasia
- Known current cervical, vaginal, or vulvar dysplasia
- Current known pregnancy diagnosis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Cohort 1 - AUB / PMB
Patients ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). Patients ages 18 - 44 years of age, presenting with abnormal uterine bleeding (AUB) and a risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 2 - Biopsy-proven EC or AEH or EIN
Patients ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 3 - Cervix pathology
Patients ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 4 - Benign Uterine Pathology
Patients with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All patients enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 5 - Healthy Control Women
Healthy patients with a uterus, ≥45 years of age presenting for GYN wellness exam to serve as a control group. These patients will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These patients will not have known or clinically suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)
Patients ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients may have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
|
Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)
Patients ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment. |
A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
Andere namen:
A blood sample will be collected from each participant prior to undergoing any exams or procedures. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within vaginal fluid in a larger, more diverse cohort.
Tijdsspanne: 18 months
|
Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development. |
18 months
|
|
Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within vaginal fluid and plasma in a larger, more diverse cohort.
Tijdsspanne: 18 months
|
Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development. |
18 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Using 95% specificity cutoffs of the final MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology
Tijdsspanne: 18 months
|
As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test. |
18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jamie N. Bakkum-Gamez, M.D., Mayo Clinic
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Endocriene klierneoplasmata
- Ovariële ziekten
- Adnexale ziekten
- Genitale neoplasmata, vrouwelijk
- Gonadale aandoeningen
- Voorstadia van kanker
- Baarmoederhalsaandoeningen
- Baarmoeder Neoplasmata
- Ovariumneoplasmata
- Baarmoeder Cervicale Neoplasmata
- Endometriumneoplasmata
- Baarmoederhalsdysplasie
- Endometriumhyperplasie
- Onderzoekstechnieken
- Exemplaarbehandeling
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Buren
- Chirurgische procedures, operatief
- Bloedspecimenverzameling
Andere studie-ID-nummers
- 20-012833
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .